Investigational Drug Information for TAK-788
✉ Email this page to a colleague
What is the development status for investigational drug TAK-788?
TAK-788 is an investigational drug.
There have been 11 clinical trials for TAK-788.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 6th 2020.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Liver Diseases. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., Takeda, and Ariad Pharmaceuticals.
There are two US patents protecting this investigational drug and fifty-eight international patents.
Summary for TAK-788
| US Patents | 2 |
| International Patents | 58 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2020-01-06) |
| Vendors | 43 |
Recent Clinical Trials for TAK-788
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788 | Takeda | Phase 2 |
| A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants | Takeda | Phase 1 |
| A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys | Millennium Pharmaceuticals, Inc. | Phase 1 |
Clinical Trial Summary for TAK-788
Top disease conditions for TAK-788
Top clinical trial sponsors for TAK-788
US Patents for TAK-788
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-788 | ⤷ Subscribe | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (Cambridge, MA) | ⤷ Subscribe |
| TAK-788 | ⤷ Subscribe | Heteroaryl compounds for kinase inhibition | ARIAD Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-788
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-788 | Australia | AU2015277786 | 2034-06-19 | ⤷ Subscribe |
| TAK-788 | Australia | AU2019206024 | 2034-06-19 | ⤷ Subscribe |
| TAK-788 | Brazil | BR112016029662 | 2034-06-19 | ⤷ Subscribe |
| TAK-788 | Canada | CA2949793 | 2034-06-19 | ⤷ Subscribe |
| TAK-788 | Chile | CL2016003222 | 2034-06-19 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
